Dianthus Therapeutics Files 8-K Report
Ticker: DNTH · Form: 8-K · Filed: Sep 8, 2025 · CIK: 1690585
| Field | Detail |
|---|---|
| Company | Dianthus Therapeutics, INC. /De/ (DNTH) |
| Form Type | 8-K |
| Filed Date | Sep 8, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: corporate-action, disclosure
TL;DR
Dianthus Therapeutics (formerly Magenta) filed an 8-K on 9/8/25 covering Reg FD, other events, and financials.
AI Summary
On September 8, 2025, Dianthus Therapeutics, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Other Events, along with Financial Statements and Exhibits. Dianthus Therapeutics, Inc. was formerly known as Magenta Therapeutics, Inc. until a name change on November 21, 2016.
Why It Matters
This 8-K filing provides an update on Dianthus Therapeutics' corporate activities and disclosures, which is important for investors to stay informed about the company's regulatory compliance and operational events.
Risk Assessment
Risk Level: low — The filing is a routine 8-K report detailing corporate events and disclosures, not indicating any immediate financial distress or significant operational changes.
Key Numbers
- 1231 — Fiscal Year End (Indicates the company's financial reporting cycle.)
Key Players & Entities
- Dianthus Therapeutics, Inc. (company) — Registrant
- Magenta Therapeutics, Inc. (company) — Former company name
- September 8, 2025 (date) — Date of report
- November 21, 2016 (date) — Date of name change
- 001-38541 (other) — SEC File Number
FAQ
What is the primary purpose of this 8-K filing for Dianthus Therapeutics, Inc.?
The primary purpose is for Regulation FD Disclosure, Other Events, and to include Financial Statements and Exhibits.
When was Dianthus Therapeutics, Inc. formerly known as?
Dianthus Therapeutics, Inc. was formerly known as Magenta Therapeutics, Inc.
On what date did the company change its name from Magenta Therapeutics, Inc.?
The date of the name change was November 21, 2016.
What is the SEC file number for Dianthus Therapeutics, Inc.?
The SEC file number is 001-38541.
What is the principal executive office address for Dianthus Therapeutics, Inc.?
The address is 7 Times Square, 43rd Floor, New York, New York, 10036.
Filing Stats: 643 words · 3 min read · ~2 pages · Grade level 11.2 · Accepted 2025-09-08 08:01:42
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 Par Value DNTH The Nasdaq Capital M
Filing Documents
- d933929d8k.htm (8-K) — 27KB
- d933929dex991.htm (EX-99.1) — 43KB
- d933929dex992.htm (EX-99.2) — 39KB
- g933929ex99_2s10g1.jpg (GRAPHIC) — 96KB
- g933929ex99_2s11g1.jpg (GRAPHIC) — 119KB
- g933929ex99_2s12g1.jpg (GRAPHIC) — 97KB
- g933929ex99_2s13g1.jpg (GRAPHIC) — 94KB
- g933929ex99_2s14g1.jpg (GRAPHIC) — 105KB
- g933929ex99_2s15g1.jpg (GRAPHIC) — 105KB
- g933929ex99_2s16g1.jpg (GRAPHIC) — 94KB
- g933929ex99_2s17g1.jpg (GRAPHIC) — 92KB
- g933929ex99_2s18g1.jpg (GRAPHIC) — 82KB
- g933929ex99_2s19g1.jpg (GRAPHIC) — 101KB
- g933929ex99_2s1g1.jpg (GRAPHIC) — 106KB
- g933929ex99_2s20g1.jpg (GRAPHIC) — 75KB
- g933929ex99_2s21g1.jpg (GRAPHIC) — 105KB
- g933929ex99_2s22g1.jpg (GRAPHIC) — 111KB
- g933929ex99_2s23g1.jpg (GRAPHIC) — 83KB
- g933929ex99_2s24g1.jpg (GRAPHIC) — 32KB
- g933929ex99_2s25g1.jpg (GRAPHIC) — 91KB
- g933929ex99_2s26g1.jpg (GRAPHIC) — 94KB
- g933929ex99_2s27g1.jpg (GRAPHIC) — 117KB
- g933929ex99_2s28g1.jpg (GRAPHIC) — 113KB
- g933929ex99_2s29g1.jpg (GRAPHIC) — 112KB
- g933929ex99_2s2g1.jpg (GRAPHIC) — 150KB
- g933929ex99_2s30g1.jpg (GRAPHIC) — 102KB
- g933929ex99_2s31g1.jpg (GRAPHIC) — 23KB
- g933929ex99_2s32g1.jpg (GRAPHIC) — 97KB
- g933929ex99_2s3g1.jpg (GRAPHIC) — 70KB
- g933929ex99_2s4g1.jpg (GRAPHIC) — 26KB
- g933929ex99_2s5g1.jpg (GRAPHIC) — 115KB
- g933929ex99_2s6g1.jpg (GRAPHIC) — 107KB
- g933929ex99_2s7g1.jpg (GRAPHIC) — 126KB
- g933929ex99_2s8g1.jpg (GRAPHIC) — 130KB
- g933929ex99_2s9g1.jpg (GRAPHIC) — 35KB
- g933929g0908081536328.jpg (GRAPHIC) — 4KB
- g933929g0908081949516.jpg (GRAPHIC) — 3KB
- 0001193125-25-197751.txt ( ) — 4399KB
- dnth-20250908.xsd (EX-101.SCH) — 3KB
- dnth-20250908_lab.xml (EX-101.LAB) — 18KB
- dnth-20250908_pre.xml (EX-101.PRE) — 11KB
- d933929d8k_htm.xml (XML) — 4KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits . The following exhibit is being furnished herewith: EXHIBIT INDEX Exhibit No. Description 99.1 Data Press Release, dated September 8, 2025 99.2 Data Presentation, dated September 8, 2025 104 Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. DIANTHUS THERAPEUTICS, INC. Date: September 8, 2025 By: /s/ Adam M. Veness, Esq. Adam M. Veness, Esq. SVP, General Counsel and Secretary